Drug Search Results
More Filters [+]

Codrituzumab

Alternative Names: codrituzumab, gc33, ro5137382
Latest Update: 2024-01-09
Latest Update Note: News Article

Product Description

Mechanisms of Action: GPC3 Inhibitor

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Chugai
Company Location: NEW YORK NY 10271
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Codrituzumab

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Hepatoblastoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT04928677

P1

Recruiting

Hepatoblastoma

2025-06-01

Recent News Events